David P Jenkins
Overview
Explore the profile of David P Jenkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim N, DArmini A, Howard L, Jenkins D, Jing Z, Mayer E, et al.
Pulm Ther
. 2024 Nov;
11(1):101-116.
PMID: 39520648
Introduction: Evidence for use of pulmonary arterial hypertension targeted-therapies in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is limited. In MERIT-1, the endothelin receptor antagonist macitentan improved hemodynamic and functional...
2.
Delcroix M, Pepke-Zaba J, DArmini A, Fadel E, Guth S, Hoole S, et al.
Circulation
. 2024 Sep;
150(17):1354-1365.
PMID: 39286890
Background: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH....
3.
Madani M, Wiedenroth C, Jenkins D, Fadel E, de Perrot M
Ann Thorac Surg
. 2024 Sep;
PMID: 39265713
Chronic thromboembolic pulmonary hypertension (CTEPH) is a consequence of unresolved organized thromboembolic obstruction of the pulmonary arteries, which can cause pulmonary hypertension and right ventricular failure. Owing to its subtle...
4.
Chiu S, Bunclark K, Appenzeller P, Ghani H, Taboada D, Sheares K, et al.
J Heart Lung Transplant
. 2024 Sep;
44(1):25-32.
PMID: 39265669
Background: Previous studies have demonstrated the safety of pulmonary endarterectomy (PEA) across body mass index (BMI) strata. However, long-term survival and patient-reported outcome measures by BMI strata remain unknown. We...
5.
Kim N, DArmini A, Delcroix M, Jais X, Jevnikar M, Madani M, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209473
Chronic thromboembolic pulmonary hypertension is a complication of pulmonary embolism and a treatable cause of pulmonary hypertension. The pathology is a unique combination of mechanical obstruction due to failure of...
6.
Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X, et al.
Lancet Respir Med
. 2024 Mar;
12(4):e21-e30.
PMID: 38548406
Background: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods: The phase 2, double-blind,...
7.
Wu J, El-Hassar L, Datta D, Thomas M, Zhang Y, Jenkins D, et al.
Mol Neurobiol
. 2023 Oct;
61(4):2430-2445.
PMID: 37889366
The ability of monkeys and rats to carry out spatial working memory tasks has been shown to depend on the persistent firing of pyramidal cells in the prefrontal cortex (PFC),...
8.
Chia A, Valchanov K, Ng C, Tsui S, Taghavi J, Vuylsteke A, et al.
J Heart Lung Transplant
. 2023 Sep;
43(2):241-250.
PMID: 37730188
Background: Pulmonary endarterectomy (PEA) is the guideline-recommended treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, some patients develop severe cardiopulmonary compromise before surgery, intraoperatively, or early postoperatively. This...
9.
Delcroix M, de Perrot M, Jais X, Jenkins D, Lang I, Matsubara H, et al.
Lancet Respir Med
. 2023 Aug;
11(9):836-850.
PMID: 37591299
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. Important advances have enabled better understanding, characterisation, and treatment of this condition. Guidelines recommending systematic follow-up after...
10.
Jenkins D, Martinez G, Salaunkey K, Reddy S, Pepke-Zaba J
Semin Respir Crit Care Med
. 2023 Jul;
44(6):851-865.
PMID: 37487525
Pulmonary endarterectomy (PEA) is the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (PH), provided lesions are proximal enough in the pulmonary vasculature to be surgically accessible and...